Tong et al. have recently demonstrated that LGG extracellular vesicles administration is effective in reducing inflammation in DSS-induced colitis by means of inhibition of the activation of the TLR4-NF-κB-NLRP3 axis and the consequent reduction in proinflammatory cytokines and dysbiosis correction [38]. The gene discussed is NFKB1; the disease is colitis.